Delcath SystemsDCTH
DCTH
About: Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Employees: 76
0
Funds holding %
of 6,831 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
740% more call options, than puts
Call options by funds: $3.28M | Put options by funds: $390K
340% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 5
31% more funds holding
Funds holding: 52 [Q2] → 68 (+16) [Q3]
10% more capital invested
Capital invested by funds: $81.7M [Q2] → $89.6M (+$7.85M) [Q3]
7% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 15
0% more funds holding in top 10
Funds holding in top 10: 3 [Q2] → 3 (+0) [Q3]
1.49% less ownership
Funds ownership: 38.12% [Q2] → 36.63% (-1.49%) [Q3]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$21
35%
upside
Avg. target
$22
38%
upside
High target
$22
41%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Craig-Hallum Chase Knickerbocker 54% 1-year accuracy 14 / 26 met price target | 35%upside $21 | Buy Maintained | 17 Jan 2025 |
HC Wainwright & Co. Swayampakula Ramakanth 31% 1-year accuracy 58 / 189 met price target | 41%upside $22 | Buy Reiterated | 14 Jan 2025 |
Financial journalist opinion
Based on 6 articles about DCTH published over the past 30 days
Negative
Yahoo Finance
2 days ago
Biotech walks a 'tightrope' amid unclear funding, regulations
Earlier this week, the Trump administration froze and then rescinded the freeze on federal funding for several programs, including research funding that the biotech industry relies on. Clear Street senior equity analyst and director of research, Mara Goldstein, sits down with Julie Hyman and Josh Lipton on Market Domination to discuss how to play the biotech sector as Trump's second term in the White House is underway.
Positive
Zacks Investment Research
2 days ago
Delcath Systems (DCTH) is on the Move, Here's Why the Trend Could be Sustainable
Delcath Systems (DCTH) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Neutral
Business Wire
4 days ago
Delcath Systems to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference from February 11-12, 2025 at The Cliff Lodge in Snowbird, UT. About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT Delcath Systems, Inc. is an interventional oncology company focu.
Positive
Zacks Investment Research
2 weeks ago
Recent Price Trend in Delcath Systems (DCTH) is Your Friend, Here's Why
Delcath Systems (DCTH) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Neutral
Business Wire
2 weeks ago
Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced preliminary financial results for the fourth quarter and year-ended December 31, 2024. Preliminary Fourth Quarter and Full-Year 2024 Financial Results (unaudited) Total fourth quarter and full year revenue expected to be approximately $15.1 million and $37.2 million, respe.
Neutral
Business Wire
4 weeks ago
Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted an equity award, previously approved by the Company's Compensation Committee, as a material inducement to the employment of an individual whose employment commenced on November 4, 2024. The grant totaled the right to purchase 30,000 shares of the Company.
Neutral
Business Wire
1 month ago
Delcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant Exercises
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the exercise of 1.7 million Series E and E1 warrants which resulted in $16.3 million of funding. Approximately 6.6% of the warrants exercised were subject to cashless exercise provisions. The warrants, issued in July and August 2019 as a component of a private placement, h.
Neutral
Business Wire
2 months ago
Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the U.S. Food and Drug Administration (FDA) has completed its 30-day review of the Company's Investigational New Drug (IND) application for a Phase 2 clinical trial evaluating HEPZATO™ in combination with standard of care (SOC) for liver-dominant metastatic colorectal cancer (mCRC). With the FDA's revie.
Positive
Seeking Alpha
2 months ago
Delcath Begins Platform Expansion With Two Phase 2 Trials
Delcath's Q3 US sales hit $10 million. This unlocked $25 million in cash from its Tranche B Warrants, which will fund its Phase 2 trials for mCRC and mBC. HEPZATO KIT's hospital rollout is progressing well. Delcath plans to end the year with 15 centers and end 2025 with 30. Treatment has gone well at UCLA. Three retrospective clinical trials and the FOCUS trial's subgroup analysis add to the growing body of evidence which shows PHP's effectiveness in treating mUM and other tumor types.
Positive
Seeking Alpha
2 months ago
Delcath Systems: Q3 Earnings Reveal HEPZATO KIT And CHEMOSAT Growth
Delcath Systems' Q3 earnings revealed strong growth with $11.2M in revenue, driven by HEPZATO and CHEMOSAT sales, and an 85% gross margin. The company is expanding its commercial footprint with 12 active treatment centers and plans to reach 30 by the end of 2025. Promising growth drivers include new cancer indications for HEPZATO, potential label expansion, and combining with immune checkpoint inhibitors.
Charts implemented using Lightweight Charts™